Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

25 May 2020

Dr. Ting Xu of Alphamab Oncology will attend Jefferies Global Healthcare Conference Dr. Ting Xu will have an interview with Jefferies Research Analyst on Tuesday, June 2, 2020 at 8:00 (Eastern Daylight Time).
23 May 2020

Alphamab Oncology and InxMed Announce Partnership to Develop Combination Therapy of KN046 and IN10018 Alphamab Oncology is actively exploring various combination therapies to unlock the great potential of KN046.
18 May 2020

Alphamab Oncology will Present Clinical Data for KN026 at the 2020 AACR Annual Meeting Leveraging tumor suppression and group PK simulation to construct model is one our attempts to determine RP2D in early clinical settings.
15 May 2020

Alphamab Oncology Announces Positive Clinical Data for Subcutaneous Injectable anti-PD-L1 Antibody KN035 at the 2020 ASCO Annual Meeting We look forward to bringing this highly anticipated subcutaneous injection inhibitor to market as soon as possible, to benefit more patients.
14 May 2020

Alphamab Oncology will Present Phase I Clinical Data of KN046 and KN026 at the 2020 ASCO Annual Meeting We are pleased to see that the latest clinical data further validate the safety and efficacy of KN046 and KN026, and that will continue to support the development of subsequent clinical trials.
13 May 2020

Alphamab Oncology Announces Four IND Application Approvals from NMPA CDE The approval of the four IND applications marks a new milestone for our continued efforts on expanding combo treatments.
16 April 2020

Alphamab Oncology Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States KN046's Phase I clinical trials in Australia and China, along with multiple Phase II trials in China have shown a good safety profile and promising efficacy.
30 March 2020

Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China This collaboration amongst three companies not only has demonstrated how top tier innovative R&D, clinical and commercial teams in China join forces, but also could set the example of an outstanding c...
27 March 2020

Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance® (palbociclib) This Phase Ib/II clinical trial is a multicenter, open-label study, aiming to evaluate efficacy, safety and tolerability of KN026 in combination with palbociclib in patients with locally advanced unre...
24 February 2020

Four IND Applications Accepted by NMPA CDE for KN046 and KN026 New Therapies These IND applications mark that Alphamab Oncology is entering the stage of clinical study of combination therapy.

13 14 15 16 17 18 19